Centene plunges after pulling forecast on revenue pressure from Obamacare plans

Centene (CNC.N) shares plummeted over 25% in premarket trading after the health insurer withdrew its 2025 earnings forecast, citing a projected $1.8 billion decline in risk adjustment revenue from its Affordable Care Act marketplace plans, equivalent to a $2.75 per share hit. This decision, which follows UnitedHealth's earlier outlook suspension, highlights specific pressures on Centene's Obamacare business, distinct from peers' Medicaid/Medicare cost concerns, though Centene also noted elevated Medicaid medical costs. Analysts anticipate a significant impact, with Mizuho suggesting Centene's 2025 profit forecast could be halved, marking a reversal of prior outperformance in its marketplace segment.

Analysis

Centene (CNC) has experienced a severe repricing event, with its shares falling over 25% premarket following the withdrawal of its 2025 earnings forecast. The primary catalyst is a projected $1.8 billion shortfall in risk adjustment revenue from its Affordable Care Act (ACA) marketplace plans, which translates to a significant $2.75 hit to adjusted earnings per share. This issue, stemming from data across 22 states, is distinct from the broader industry pressures on Medicaid and Medicare costs previously flagged by peers like UnitedHealth, indicating a specific operational challenge for Centene in a business segment once considered an outperformer. Analyst sentiment is deeply negative, with Mizuho projecting that the initial 2025 profit forecast could be cut in half, citing concerns that medical costs could be even higher in the remaining seven states. While Centene also reported elevated Medicaid costs, the core issue represents a fundamental reversal in its marketplace business. The stock's forward P/E of 7.7x, already a discount to peers before this news, will compress further, reflecting the market's heightened perception of earnings risk and operational uncertainty.

Key Decisions for Investors

• Given the withdrawal of guidance and the potential for a 50% cut to the 2025 profit forecast, investors should treat Centene with extreme caution until the company provides a revised and credible financial outlook.
• The contagion effect on peers like UnitedHealth and Elevance warrants a portfolio review to assess specific exposure to ACA marketplace risk, as Centene's issues may signal broader instability or mispricing within that segment.
• While the dramatic share price drop creates a deep valuation discount, this may be a value trap; investors must weigh the low multiple against the significant fundamental deterioration and the high probability of further negative earnings revisions.